SCHEMBL7923592

SCHEMBL7923592

CC(C)(O)C[N+]([O-])=Cc1ccc(F)cc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.37
PTGS2 P35354 1/20 0.37
NFE2L2 Q16236 4/20 0.37
GRIN2D O15399 2/20 0.36
GRIN3B O60391 2/20 0.36
GRIN1 Q05586 2/20 0.36
GRIN2A Q12879 2/20 0.36
GRIN2B Q13224 2/20 0.36
GRIN2C Q14957 2/20 0.36
GRIN3A Q8TCU5 2/20 0.36
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
RAB9A P51151 1/20 0.35
ATM Q13315 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CYP1A1 P04798 1/20 0.33
CYP1B1 Q16678 1/20 0.33
FBP1 P09467 1/20 0.33
ACSS2 Q9NR19 1/20 0.32
HTR2A P28223 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7923570 0.82 NFE2L2 (0.35) PTGS1PTGS2NFE2L2GRIN2DGRIN3B
SCHEMBL7926807 0.80 POLB (0.38) PTGS1PTGS2NFE2L2GRIN2DGRIN3B
SCHEMBL7914607 0.79 PTGS1 (0.37) PTGS1PTGS2NFE2L2GRIN2DGRIN3B
SCHEMBL7923573 0.76 NFE2L2 (0.42) PTGS1PTGS2NFE2L2GRIN2DGRIN3B
SCHEMBL7921545 0.75 ACHE (0.36) NFE2L2MAPTRAB9AHTR2AHTR2C
SCHEMBL8441698 0.74 NFE2L2 (0.35) PTGS1PTGS2NFE2L2GRIN2DGRIN3B
SCHEMBL7926808 0.72 POLB (0.40) PTGS1PTGS2POLBMAPTRAB9A
SCHEMBL7922819 0.70 PTGS1 (0.31) PTGS1PTGS2NFE2L2GRIN2DGRIN3B
SCHEMBL7914568 0.70 NFE2L2 (0.32) PTGS1PTGS2NFE2L2POLBMAPT
SCHEMBL11414043 0.66 ALDH1A1 (0.61) NFE2L2GRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6194461-B1 USEFUL AS MEDICAMENT FOR TREATING RETINAL DEGENERATIVE DISORDERS; ALPHA-(2,4-DIFLUOROPHENYL)-N-T-BUTYLNITRONE, AND CORRESPONDING AMINES WHICH WOULD BE CONVERTED IN VIVO TO THE NITRONE, FOR EXAMPLE SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-02-27 US disclosed